Roos L. Oostendorp
Department of Medical Oncology
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX
Netherlands
Name/email consistency: high
- Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Oostendorp, R.L., Witteveen, P.O., Schwartz, B., Vainchtein, L.D., Schot, M., Nol, A., Rosing, H., Beijnen, J.H., Voest, E.E., Schellens, J.H. Invest. New. Drugs (2010)
- The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Oostendorp, R.L., Buckle, T., Beijnen, J.H., van Tellingen, O., Schellens, J.H. Invest. New. Drugs (2009)
- Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Oostendorp, R.L., van de Steeg, E., van der Kruijssen, C.M., Beijnen, J.H., Kenworthy, K.E., Schinkel, A.H., Schellens, J.H. Drug Metab. Dispos. (2009)
- Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Oostendorp, R.L., Huitema, A., Rosing, H., Jansen, R.S., Ter Heine, R., Keessen, M., Beijnen, J.H., Schellens, J.H. Clin. Cancer Res. (2009)
- Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. Oostendorp, R.L., Loftiss, J., Goel, S., Smith, D.A., Dar, M.M., Witteveen, P.O., Cohen, R.B., Lewis, L.D., Kurian, S., Patnaik, A., Rosing, H., Beijnen, J.H., Voest, E.E., Burris, H., J, N. Int. J. Clin. Pharmacol. Ther (2009)
- The biological and clinical role of drug transporters at the intestinal barrier. Oostendorp, R.L., Beijnen, J.H., Schellens, J.H. Cancer Treat. Rev. (2009)